DUSP28 contributes to human hepatocellular carcinoma via regulation of the p38 MAPK signaling

Wang,Dong; Han,Sheng; Peng,Rui; Jiao,Chenyu; Wang,Xing; Han,Zeguang; Li,Xiangcheng

doi:10.3892/ijo.2014.2653

DUSP28 contributes to human hepatocellular carcinoma via regulation of the p38 MAPK signaling

Authors:
- Dong Wang
- Sheng Han
- Rui Peng
- Chenyu Jiao
- Xing Wang
- Zeguang Han
- Xiangcheng Li
View Affiliations

Affiliations: Liver Transplantation Center, First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Liver Transplantation, Ministry of Public Health, Nanjing, Jiangsu, P.R. China, Shanghai‑MOST Key Laboratory for Disease and Health Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, P.R. China
Published online on: September 16, 2014 https://doi.org/10.3892/ijo.2014.2653
Pages: 2596-2604

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DUSP28, a member of the atypical dual‑specificity phosphatase (DUSP) family, is a candidate tumor‑related gene in hepatocellular carcinoma (HCC) selected by genome‑wide approach, but its pathological role in HCC has not been elucidated. Here, we report for the first time that DUSP28 is involved in HCC progression. Quantitative real‑time PCR and semi‑quantitative RT‑PCR showed notably elevated expression of DUSP28 in HCC specimens compared to that in corresponding adjacent non‑tumor liver. DUSP28 overexpression promoted HCC cell proliferation, colony formation and soft agar colony formation in vitro while DUSP28 knockdown resulted in the opposite effects. Furthermore, the flow cytometric analysis indicated that DUSP28 could lead to an increased population of cancer cells in S phase, with a concomitant decrease of cells in G1 phase. Investigation of the mechanism revealed that DUSP28 could activate the p38 mitogen‑activated protein kinase (MAPK) signaling pathway. Taken together, these data demonstrate that DUSP28 plays a significant role in HCC progression and may be a feasible molecular target for anti‑cancer therapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinogenesis (review). Int J Oncol. 42:1133–1138. 2013.PubMed/NCBI
3	Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
4	Yang Y, Nagano H, Ota H, et al: Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 141:196–202. 2007. View Article : Google Scholar : PubMed/NCBI
5	Hwang S, Moon DB and Lee SG: Liver transplantation and conventional surgery for advanced hepatocellular carcinoma. Transplant Int. 23:723–727. 2010. View Article : Google Scholar
6	Abdel-Wahab M, Sultan AM, Fathy OM, et al: Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology. 60:1847–1853. 2013.PubMed/NCBI
7	Sandhu DS, Baichoo E and Roberts LR: Fibroblast growth factor signaling in liver carcinogenesis. Hepatology. 59:1166–1173. 2014. View Article : Google Scholar : PubMed/NCBI
8	Guégan JP, Ezan F, Théret N, Langouët S and Baffet G: MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells. Carcinogenesis. 34:38–47. 2013.PubMed/NCBI
9	Fuchs BC, Hoshida Y, Fujii T, et al: Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology. 59:1577–1590. 2014. View Article : Google Scholar : PubMed/NCBI
10	Gao W, Kim H, Feng M, et al: Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology. 60:576–587. 2014. View Article : Google Scholar : PubMed/NCBI
11	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
13	Jeong DG, Wei CH, Ku B, et al: The family-wide structure and function of human dual-specificity protein phosphatases. Acta Crystallogr D Biol Crystallogr. 70:421–435. 2014. View Article : Google Scholar : PubMed/NCBI
14	Wu GS: Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev. 26:579–585. 2007. View Article : Google Scholar : PubMed/NCBI
15	Keyse SM: Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27:253–261. 2008. View Article : Google Scholar : PubMed/NCBI
16	Haagenson KK and Wu GS: Mitogen activated protein kinase phosphatases and cancer. Cancer Biol Ther. 9:337–340. 2010. View Article : Google Scholar : PubMed/NCBI
17	Haagenson KK and Wu GS: The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev. 29:143–149. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sekine Y, Tsuji S, Ikeda O, et al: Regulation of STAT3-mediated signaling by LMW-DSP2. Oncogene. 25:5801–5806. 2006. View Article : Google Scholar : PubMed/NCBI
19	Sekine Y, Ikeda O, Hayakawa Y, et al: DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118. Oncogene. 26:6038–6049. 2007. View Article : Google Scholar : PubMed/NCBI
20	Li JP, Fu YN, Chen YR and Tan TH: JNK pathway-associated phosphatase dephosphorylates focal adhesion kinase and suppresses cell migration. J Biol Chem. 285:5472–5478. 2010. View Article : Google Scholar : PubMed/NCBI
21	Rahmouni S, Cerignoli F, Alonso A, et al: Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol. 8:524–531. 2006. View Article : Google Scholar : PubMed/NCBI
22	Shang X, Vasudevan SA, Yu Y, et al: Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene. 29:4938–4946. 2010. View Article : Google Scholar : PubMed/NCBI
23	Klinger S, Poussin C, Debril MB, Dolci W, Halban PA and Thorens B: Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Diabetes. 57:584–593. 2008. View Article : Google Scholar : PubMed/NCBI
24	Patterson KI, Brummer T, O’Brien PM and Daly RJ: Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 418:475–489. 2009.PubMed/NCBI
25	Prabhakar S, Asuthkar S, Lee W, et al: Targeting DUSPs in glioblastomas - wielding a double-edged sword? Cell Biol Int. 38:145–153. 2014. View Article : Google Scholar : PubMed/NCBI
26	Nunes-Xavier C, Romá-Mateo C, Ríos P, et al: Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem. 11:109–132. 2011. View Article : Google Scholar : PubMed/NCBI
27	Ríos P, Nunes-Xavier CE, Tabernero L, Köhn M and Pulido R: Dual-specificity phosphatases as molecular targets for inhibition in human disease. Antioxid Redox Signal. 20:2251–2273. 2014.PubMed/NCBI
28	Thornton TM and Rincon M: Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci. 5:44–51. 2009. View Article : Google Scholar : PubMed/NCBI
29	Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
30	Ayub A, Ashfaq UA and Haque A: HBV induced HCC: major risk factors from genetic to molecular level. Biomed Res Int. 2013:8104612013. View Article : Google Scholar : PubMed/NCBI
31	Arnoldussen YJ, Lorenzo PI, Pretorius ME, et al: The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res. 68:9255–9264. 2008. View Article : Google Scholar
32	Henkens R, Delvenne P, Arafa M, et al: Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC cancer. 8:1472008. View Article : Google Scholar : PubMed/NCBI
33	Tang JP, Tan CP, Li J, et al: VHZ is a novel centrosomal phosphatase associated with cell growth and human primary cancers. Mol Cancer. 9:1282010. View Article : Google Scholar : PubMed/NCBI
34	Deng Q, Li KY, Chen H, et al: RNA interference against cancer/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma. Hepatology. 59:518–530. 2014. View Article : Google Scholar
35	Bai L, Yoon SO, King PD and Merchant JL: ZBP-89-induced apoptosis is p53-independent and requires JNK. Cell Death Differ. 11:663–673. 2004.PubMed/NCBI
36	Yu W, Imoto I, Inoue J, Onda M, Emi M and Inazawa J: A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene. 26:1178–1187. 2007. View Article : Google Scholar : PubMed/NCBI
37	Bertoli C, Skotheim JM and de Bruin RA: Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 14:518–528. 2013. View Article : Google Scholar : PubMed/NCBI
38	Hui L, Bakiri L, Mairhorfer A, et al: p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet. 39:741–749. 2007. View Article : Google Scholar : PubMed/NCBI
39	Hui L, Bakiri L, Stepniak E and Wagner EF: p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle. 6:2429–2433. 2007. View Article : Google Scholar : PubMed/NCBI